Jingfang Ju, PhD, Professor

Jingfang Ju, PhDDr. Jingfang Ju
Director of Oncogenic Drivers and Mechanisms of Carcinogenesis,
Stony Brook Cancer Center

Basic Sciences Tower, Level 9
Stony Brook Medicine
Stony Brook, NY 11794-8691

Tel:  (631) 444-3598
Fax: (631) 444-3424
E-mail: Jingfang.Ju@stonybrookmedicine.edu

Research Interests:
Dr. Ju’s research at Renaissance School of Medicine at Stony Brook University focuses on elucidating the mechanism of translational control mediated by non-coding RNAs in cancer and translating the new discovery to clinical cancer diagnosis and therapy. His group is the first to discover that p53 regulates the expression of certain miRNAs, opening a new frontier in cancer research. Dr. Ju’s group is actively investigating the mechanism of miRNAs in proliferation, cell cycle control, chemoresistance to fluoropyrimidines and antifolates in tumor stem cells, and epithelial-to-mesenchymal transition. His group is also developing novel approaches to study post-transcriptional control mediated by miRNAs and RNA binding proteins. As for the translational research, they are interested in the investigation of miRNAs as biomarkers in cancer diagnosis and prognosis.

Institution and Location Degree Year Field of Study
Northeastern University B.S. 1989 Engineering
University of Southern California Ph. D. 1996 Biochem/Molecular Biology
Yale University Post Doc 1999 Pharmacology

Positions and Employment: 
1999-2003 Senior Research Scientist and Genomic Technology Team Leader, CuraGen Inc., CT
2004-2008 Head of the Cancer Genomics, Assistant Professor of Oncological Sciences, Mitchell Cancer Institute
2008-present Co-Director of Translational Research, Department of Pathology, Stony Brook Medicine
2009-present Graduate faculty, Molecular and Cellular Biology Program, Stony Brook Medicine
2009-present Graduate faculty, Genetics Program, Stony Brook Medicine
2013-present Affiliated faculty of The RNA Institute

Other Experience and Professional Memberships (selected):
2012-present Editorial Board, microRNA
2012-present Editorial Board, Biomarker Research
2011-present Review Editor, Frontiers in Genomics Assay Technology
2007-present Editorial Board, Canacer Genomics and Protemics
2006 Managing Editor, Frontiers in Biosciences
2005-present Member, American Society of Clinical Oncology
2004-present National Cancer Institute Study Section Member (Innovative Molecular Analysis Technology: IMAT, Applied Emerging Technology for Cancer Research, SBIR/STTR, Cancer Biomarker, BMCT, U-01, P-01, K01, R03, K99)
2003-present Member, Society of Chiniese Bioscientists in America
1993-present Member, American Association for Cancer Research

Honors (selected):
2012 Excellence in Mentoring Graduate and Postdoctoral Fellows Stony Brook Medicine Pathology
2000 Stellar Achievement Award, CuraGen Corporation
1999 National Research Service Award, NIH
1996 Glaxo Welcome Young Clinical Research Scholar Award
1992 Scholarship from Los Alamos National Laboratory Science and Alliance Program


Selected Publications:
1. Karaayvaz M, Zhai H, Ju J. miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer. Cell Death Dis. 2013.193. 4: e659; doi:10.1038/cddis.
2. Zhai H, Fesler A, Ju J. MicroRNA – A third dimension in autophagy. Cell Cycle. 2013 12(2): 246-50
3. Zhai H, Song B, Xu X, Zhu W, Ju J. Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene. 2013. 32(12):1570-9.
4. Xu X, Gnatenko D, Ju J, Hitchcock I, Martin D, Zhu W, Bahou W. Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms. Blood. 2012. 120(17):3575-85.
5. Dong P, Karaayvaz M, Kaneuchi M, Jia N, Hamada J, Watari H, Sudo S, Ju J*. Sakuragi N. Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene. 2012. July 20. [Epub ahead of print].
6. Song B, Wang Y, Titmus MA, Botchikina G, Ju J. miR-215 regulates dihydrofolate reductase and thymidylate synthase and increases chemoresistance in osteosarcoma and colon cancer. Mol. Cancer. 2010. 9:192
7. Kudo K, Xi Y, Wang Y, Song B, Chu E, Ju J, Russo J, Ju J. Translational control analysis by translationally active RNA capture/microarray analysis (TrIP-Chip). Nucleic Acids Research, 2010. 38(9):e104.
8. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 2009, 28(46):4065-74.
9. Song B, Wang Y, Kudo K, Gavin E, Xi Y, Ju J. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clinical Cancer Research.  2008, 14: 8080-8086.
10. Xi Y*, Nakajima G*, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA. 2007. 13(10):1668-74.
11. Ju J, Schmitz JC, Song B, Kudo K, Chu E. Regulation of p53 expression in response to 5-fluorouracil in human cancer RKO cells. Clinical Cancer Research. 2007. 13(14); 4245-4251.
12. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clinical Cancer Research. 2006. 12 (7): 2014-2024.